Conclusion:
Immunotherapy outcomes in small studies has shown good data for increasing survival rates at all yearly intervals in mucosal melanomas of the Head and Neck.
Larger clinical trials should be done to accurately distinguish the efficacy and survival outcomes of immunotherapy when compared to treatment modalities excluding immunotherapy.
We note that the ability to perform larger trials are limited by the rarity of mucosal melanomas of the Head and Neck.
  1. Hahn H, Lee K, Choi W, Cheong S, Myung K, Hahn H. An updated review of mucosal melanoma: Survival meta‑analysis. 2021.
  2. Patrick R, Fenske N, Messina J. Primary mucosal melanoma. 2021.
  3. Postow M, Hamid O, Carvajal R. Mucosal Melanoma: Pathogenesis, Clinical Behavior, and Management. 2021.
  4. Nassar K, Tan A. The mutational landscape of mucosal melanoma. 2021.
  5. Konuthula N, Khan M, Parasher A, Del Signore A, Genden E, Govindaraj S et al. The presentation and outcomes of mucosal melanoma in 695 patients. 2021.
  6. [Internet]. Melanomafocus.com. 2021 [cited 24 July 2021]. Available from: https://melanomafocus.com/wp-content/uploads/2020/04/AA-HN-Full-Guideline.pdf
  7. Atrash S, Makhoul I, Mizell J, Hutchins L, Mahmoud F. Response of metastatic mucosal melanoma to immunotherapy: It can get worse before it gets better. 2021.
  8. Thierauf J, Veit J, Affolter A, Bergmann C, Grünow J, Laban S et al. Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck. 2021.
  9. Cho J, Ahn S, Yoo K, Kim J, Choi S, Jang K et al. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry. 2021.
  10. D’Angelo S, Larkin J, Sosman J, Lebbé C, Brady B, Neyns B et al. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. 2021.
  11. Wang R, Jing G, Lv J, Song H, Li C, Wang X et al. Interferon-α-2b as an adjuvant therapy prolongs survival of patients with previously resected oral muscosal melanoma. 2021.
  12. Frakes J, Strom T, Naghavi A, Trotti A, Rao N, McCaffrey J et al. Outcomes of mucosal melanoma of the head and neck. 2021.
  13. K O, S T, F S, A S, I O, M U et al. [Malignant mucosal melanomas of the head and neck–collective review from six cancer hospitals] [Internet]. PubMed. 2021 [cited 24 July 2021]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/3783975
  14. Long G, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V et al. Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF-Mutated Melanoma. 2021.
  15. Studentova H, Kalabova H, Koranda P, Chytilova K, Kucerova L, Melichar B et al. Immunotherapy in mucosal melanoma: a case report and review of the literature. 2021.
  16. Jarrom D, Paleri V, Kerawala C, Roques T, Bhide S, Newman L et al. Mucosal melanoma of the upper airways tract mucosal melanoma: A systematic review with meta-analyses of treatment. 2021.